Between January 1, 2019 and December 31, 2021, Novo will pay to us 12% of annual net sales of Macrilen in the U.S. Between January 1, 2022 and December 31, 2027, Novo will pay to us (i) 4% of any ..............
Royalty revenue AEterna Strongbridge 12% Royalty income 15% Q1 19 10T 13T Q2 19 6T 8T Q3 19 7T 8T Q4 19 13T 16T Q1 20 11T 14T Q2 20 8T 10T
Von Novo zu AEterna supply chain costs Q1 + Q2 $839T Q3 $255T Q4 $ 65T Q1 $ 41T Q2 $ 40T
The Company agreed, in the Interim Supply Arrangement to the License Agreement, to supply ingredients for the manufacture of Macrilen™ (macimorelin) during an interim period at a price that is set ‘at cost’ without any profit margin. In November 2019, Novo contracted AEZS Germany, to provide supply chain services including API batch production and delivery of certain API and semi-finished goods, as well as the provision of ongoing support activities. During the three-month period ended March 31, 2020, the Company invoiced Novo $41 for supply chain activities (2019 – $6) and invoiced $1,016 in product sales |